Stocks of Sarepta Therapeutics Inc (NASDAQ:SRPT) traded higher last session on Wall Street, up 13.68% to $76.52.
According to the data, Sarepta Therapeutics Inc (NASDAQ:SRPT) has 19 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $220.00 and a low of $40.00, we find $146.00. Given the previous closing price of $67.31, this indicates a potential upside of 116.91 percent. SRPT stock price is now -34.61% away from the 50-day moving average and -37.70% away from the 200-day moving average. The market capitalization of the company currently stands at $7.14B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
A total of 5 analysts have issued a hold rating and 12 have given it a buy rating. Brokers who have rated the stock have averaged $140.00 as their price target over the next twelve months.
In other news, Chambers Michael Andrew, Director bought 9,979 shares of the company’s stock on Aug 14. The stock was bought for $1,092,429 at an average price of $109.47. Upon completion of the transaction, the Director now directly owns 246,996 shares in the company, valued at $18.9 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 11, Director Chambers Michael Andrew bought 23,686 shares of the business’s stock. A total of $2,559,272 was incurred on buying the stock at an average price of $108.05. This leaves the insider owning 237,017 shares of the company worth $18.14 million. Insiders disposed of 28,587 shares of company stock worth roughly $2.19 million over the past 1 year. A total of 5.69% of the company’s stock is owned by insiders.
Wednesday’s opening bell rang with an opening price of $57.63 for Sarepta Therapeutics Inc (NASDAQ: SRPT). During the past 12 months, Sarepta Therapeutics Inc has had a low of $55.25 and a high of $159.89. As of last week, the company has a debt-to-equity ratio of 1.84, a current ratio of 4.96, and a quick ratio of 4.50. The fifty day moving average price for SRPT is $117.02 and a two-hundred day moving average price translates $122.79 for the stock.
The latest earnings results from Sarepta Therapeutics Inc (NASDAQ: SRPT) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.27, beating analysts’ expectations of -$1.78 by 1.51. This compares to -$2.65 EPS in the same period last year. The net profit margin was -90.46% and return on equity was -123.67% for SRPT. The company reported revenue of $261.24 million for the quarter, compared to $233.49 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.89 percent. For the current quarter, analysts expect SRPT to generate $288.5M in revenue.
